Oral Medication to Treat Alzheimer’s Disease

Evaluation of a investigational oral medication for patients with Alzheimer’s Disease.

A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve- Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil.

This is a one-year study with a one in three chance of receiving placebo. All patients will have the opportunity to receive the study medication at the end of the one year blinded portion.

Major Inclusion/Exclusion Criteria:

  • Age greater or equal to 50 years old
  • Must be taking Aricept 10 mg for a minimum of six months
  • Must be off all other Alzheimer’s medications for 90 days prior to screening
  • Must have a caregiver for a minimum of three hours a day five days a week
  • History of Insulin-dependent Diabetes is excluded
  • History of cancer within the past five years is excluded (except for skin and prostate cancer)